Voyager Therapeutics (VYGR) Current Leases (2019 - 2026)

Voyager Therapeutics has disclosed Current Leases across 8 years of filings, most recently posting $6.9 million for Q2 2026.

• In Q2 2026, Current Leases fell 9.96% year-over-year to $6.9 million; the TTM figure through Jun 2026 stood at $6.9 million (down 9.96% YoY), while the FY2025 annual figure was $7.8 million, up 8.48% from the prior year.
• Current Leases came in at $6.9 million for Q2 2026 at Voyager Therapeutics, down from $7.4 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $7.8 million in Q3 2025 to a low of $2.5 million in Q2 2022.
• Average Current Leases over 5 years is $5.4 million, with a median of $6.3 million recorded in 2024.
• Year-over-year, Current Leases tumbled 49.17% in 2022 and jumped 125.84% in 2024.
• Over 5 years, Current Leases stood at $2.8 million in 2022, then climbed by 12.99% to $3.2 million in 2023, then jumped by 125.84% to $7.2 million in 2024, then climbed by 8.48% to $7.8 million in 2025, then dropped by 12.3% to $6.9 million in 2026.
• Per Business Quant data, the three most recent Current Leases figures were $6.9 million in Q2 2026, $7.4 million in Q1 2026, and $7.8 million in Q4 2025.